Tempus AI is scaling quickly in oncology diagnostics and data licensing, but losses, negative free cash flow, and leverage keep the stock in Hold territory.
Tempus AI (TEM) is building a differentiated precision-medicine platform, but the stock already reflects much of the growth story. Q2 2026 revenue reached $382.5M, up 22% year over year, while oncology volume rose 31% and Insights revenue grew 36%. Management also raised 2026 revenue guidance to $1.595B to $1.605B and reaffirmed adjusted EBITDA of approximately $65M.
The operating trend is improving, yet the financial foundation remains unfinished. Q2 operating loss was $75.9M, 2025 free cash flow was negative $245.4M, and June 2026 debt of $1.37B exceeded cash of $599.6M. TTM EPS was negative $1.79, and the stock price of $66.72 sat above the analyst consensus target of $62.64. For a moderate-risk investor with a medium-term horizon, those facts support a Hold rather than a chase.
The central investment argument is simple: Tempus has real growth engines in oncology diagnostics, data licensing, and AI applications, but the company must convert those assets into durable GAAP profitability and positive cash flow before the valuation earns a clear premium. The platform has promise. The balance sheet still keeps one hand on the brake.
Tempus AI is a U.S. healthcare technology company founded in 2015 and headquartered in Chicago. It listed on Nasdaq on June 14, 2024, and had approximately 3,800 employees. Eric Lefkofsky serves as co-founder, chief executive officer, president, and chairman.
The business combines clinical diagnostics with data and applications. Diagnostics includes next-generation sequencing, PCR profiling, pathology, hereditary testing, liquid biopsy, solid-tumor testing, and minimal residual disease testing. Data and Applications includes Lens, Insights, Trials, Next, and algorithm-based clinical tools.
Diagnostics remains the larger operating engine. Q2 2026 Diagnostics revenue was $289.3M, up from $241.8M in Q2 2025. Diagnostics gross profit increased to $181.1M from $142.1M, while gross margin expanded to 62.6% from 58.8%. Management highlighted 31% year-over-year oncology volume growth and 20% Diagnostics revenue growth.
Data and Applications generated Q2 revenue of $93.2M, compared with $72.8M a year earlier. Gross profit reached $65.4M, and the segment produced a 70.2% gross margin. Insights, the data licensing and modeling business, grew 36% year over year in the quarter. Its higher margin profile gives Tempus an important mix-shift opportunity as the business scales.
The first quarter showed even faster momentum in both areas. Diagnostics revenue was $261.1M, up almost 35%, while Data and Applications revenue was $87.0M, up 40.5%. The Q1 call also cited three consecutive quarters with bookings above $100M and a growing total contract value base. That combination of clinical volume and contracted data work supports revenue visibility, although it does not remove the need for cash discipline.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Tempus xT is the flagship solid-tumor assay, while xR, xF, xG, xH, and MRD extend the platform across liquid biopsy, hereditary disease, hematologic malignancies, and post-treatment monitoring. The investor presentation identified FDA approval for tumor-only xT CDx as a major product milestone. Management said the move can shift the solid-tumor portfolio from LDT pricing of approximately $2,900 to xT CDx pricing of $4,500 beginning in 2027.
MRD is the fastest-growing product by volume, although it remains small. Q2 MRD volume reached 9,000 tests, up from 6,500 in Q1 and 4,700 in Q4 2025. Management stated that approximately 97% of MRD tests are tumor-informed and that the company has kept its MRD sales force limited while reimbursement develops. That restraint protects near-term economics, but it also limits the speed of commercial expansion.
Tempus also launched xH, Rare Whole Genome, and Tempus Preview. Preview is designed to surface key mutation predictions within roughly 24 hours of tissue receipt. These products expand the platform beyond a single oncology assay and improve the odds that a physician relationship produces multiple testing orders over time.
Tempus claims a multimodal data environment containing more than 500 petabytes of data, over 8.6 million de-identified patient records, 1.4 billion documents, and 1.6 billion pages of clinical text. The data connects to analytics and model-building infrastructure using both CPUs and GPUs. This architecture gives Tempus a broader asset base than a company selling a single laboratory test.
The strategic advantage is the link between testing, data, and applications. Each diagnostic order can add clinical and molecular information to the platform. That information can support physician tools, pharma research, clinical trial design, and new algorithms. The model is a network effect in structure, though its investment value depends on Tempus proving that additional data produces higher revenue and margins rather than only higher infrastructure costs.
Tempus reported an approximately 40% attach rate for algorithms on solid-tumor oncology assays. Its examples include tumor-origin prediction, homologous recombination deficiency, and an immune profile score intended to refine traditional measures such as tumor mutational burden. Higher attach rates can raise revenue per test without requiring a proportional increase in patient volume.
Tempus operates a laboratory and software model rather than a conventional equipment manufacturing supply chain. Its operating inputs include clinical samples, sequencing and pathology capabilities, data infrastructure, specialized employees, reimbursement processes, and computing capacity. The company's 3,800 employees support that combined clinical and technology footprint.
Acquisitions have expanded the operating footprint. Tempus completed its $692.3M acquisition of Ambry Genetics on February 3, 2025, recording $234.0M of customer relationships and $114.0M of developed technology related to the transaction. The 2025 audit excluded Ambry and Paige from the internal-control assessment because they were acquired during the year. Together, those subsidiaries represented approximately 11% of related consolidated assets and 29% of related consolidated revenue.
Cash conversion has been uneven. Quarterly free cash flow was positive $34.7M in Q2 2025, then negative $127.9M in Q3, negative $43.1M in Q4, negative $83.3M in Q1 2026, and negative $18.6M in Q2 2026. The CFO attributed Q1 pressure to payables, bonuses, and the timing of large Insights contracts moving from prepayments or deferred revenue to quarterly payments. That explanation identifies a working-capital pattern, not a permanent solution.
Tempus operates across several large adjacent markets. Its filing materials identify a $38B clinical trial services market, a $46B biomarker discovery market, and a $29B third-party real-world evidence market. Those categories align directly with Tempus's data licensing, modeling, and clinical trial products.
The broader life science instrumentation market was estimated at $63.4B in 2025, with a projection of $92.5B by 2031 and a 6.5% compound annual growth rate. Life science analytics was estimated at $40.0B in 2025 and $68.8B by 2030, representing an 11.4% compound annual growth rate. These figures favor Tempus's exposure to software, analytics, and AI more than they favor a traditional laboratory-tools company.
NGS is another important market driver. Mordor Intelligence cited a 16.9% compound annual growth rate for NGS in the U.S. life science tools market through 2031. Tempus's 31% Q2 oncology volume growth exceeded that market reference, giving the company a record of outgrowing the underlying testing category.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Tempus serves three clear customer groups: physicians and health systems, pharmaceutical and biotechnology companies, and clinical research organizations. The company reported connections to more than 9,000 providers, approximately 65% of U.S. academic medical centers, and approximately 55% of U.S. oncologists.
Pharma customers include AstraZeneca, GSK, Merck, Bristol Myers Squibb, and Gilead. The Q1 call said Merck signed a large strategic data and modeling collaboration and that Gilead expanded its relationship with Tempus by a significant amount. Management also described nearly half a dozen customers with agreements at the $100M-plus level over multiple years.
The customer mix creates both strength and concentration risk. Multi-year pharma contracts can improve visibility and carry high margins, while clinical diagnostics produces a broader stream of individual orders. The 2025 filing identified variable consideration in clinical revenue as a critical audit matter because reimbursement estimates depend on historical collections, payer-specific factors, and anticipated reimbursement trends.
In precision oncology and genomics, Tempus competes with Foundation Medicine, Caris Life Sciences, Guardant Health (GH), NeoGenomics (NEO), Natera (NTRA), ResolutionBio, Quest Diagnostics, and Labcorp. In data and clinical services, the competitive set includes Fortrea (FTRE), ICON, Syneos, PPD, and other clinical-trial matching providers.
The competitive field is fragmented because rivals tend to be strongest in different parts of the workflow. Foundation Medicine has a recognized oncology testing franchise, Guardant focuses heavily on liquid biopsy, Natera has a strong presence in monitoring, and large laboratories offer distribution and reimbursement scale. Tempus's counterposition is the combination of diagnostics, clinical workflow software, multimodal data, and pharma modeling.
Tempus has demonstrated commercial traction, but scale alone is not a moat. Larger diagnostics companies have deeper capital resources, and specialist competitors can concentrate research and sales investment on one assay category. Tempus therefore needs continued oncology volume growth, contract expansion, algorithm adoption, and improving margins to make its broader platform economically difficult to replicate.
The macro backdrop favors data-intensive healthcare tools. Deloitte reported that approximately 60% of life sciences executives were closely monitoring generative AI or digital transformation as a key emerging trend. Gartner identified AI, multiomics, cloud platforms, and digital trials as technologies reshaping life sciences research and development.
Regulation is a direct financial variable for Tempus. FDA approval of tumor-only xT CDx supports a higher pricing path, while the company's xF submission and additional assay approvals remain part of the broader reimbursement strategy. Management said xF would have no impact on 2026 pricing or average selling prices, which makes the xT CDx pricing transition more relevant to the near-term model.
Privacy, artificial-intelligence oversight, intellectual-property protection, and health-data regulation are material business issues identified in Tempus risk disclosures. The company also faces payer decisions that affect clinical revenue. These risks matter more for TEM than for a conventional software company because its data originates in sensitive healthcare records and its tests influence medical decisions.
June 2026 debt of $1.37B still exceeded cash of $599.6M, leaving Tempus with a leverage profile that constrains flexibility despite improving operations.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose to $382.5M and gross margin improved, but a $75.9M operating loss shows the company is still not close to GAAP profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue guidance to $1.595B-$1.605B and reaffirmed adjusted EBITDA of about $65M, signaling continued top-line momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With the stock at $66.72 versus a $62.64 analyst consensus target, Tempus is trading above near-term expectations even before it reaches durable profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $65, which supports a Hold as the market already discounts much of Tempus AI’s growth story.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Tempus AI has moved beyond the concept stage. Q2 2026 revenue reached $382.5M, oncology volume grew 31%, Insights grew 36%, gross margin reached 64.4%, and adjusted EBITDA turned positive at $8.0M. The company also has named pharma relationships, a large multimodal data environment, and a product portfolio that spans testing, clinical workflows, and research.
The investment case still requires financial proof. Debt of $1.37B, cash of $599.6M, negative operating income, and negative free cash flow leave less room for execution mistakes than the growth narrative implies. The projected EPS ramp is encouraging, but the wide 2027 and 2028 estimate ranges show that profitability remains a forecast rather than an established operating fact.
At $66.72, TEM is a Hold for a moderate-risk investor. The platform can become a market leader in data-rich precision medicine, but the stock needs continued volume growth and visible cash generation to justify a stronger rating. Patience is more attractive than pursuit at the current price.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Tempus AI, Inc. (TEM) climbs after a positive Merck-Moderna melanoma result sparked fresh enthusiasm for precision oncology and MRD testing. The rally also follows solid Q2 results and renewed attention on Tempus’ Personalis acquisition, though the stock remains volatile and richly valued.
TEM’s 24.1% headline-free surge looks like investors repricing a real profitability inflection, not chasing an empty AI story. Q2 revenue growth, a guidance raise and a path to positive cash flow give the rally a fundamental anchor despite expensive valuation.
TEM's sharp rally is absorbing Personalis dilution risk because the growth engine is getting harder for the market to ignore. Revenue growth, MRD adoption and repeated earnings beats give the bull case more weight than the deal's near-term optics.